Background: Zidebactam is a b-lactam enhancer antibiotic with a dual mechanism of action involving binding to Gram-negative PBP2 and b-lactamase inhibition. Cefepime combined with zidebactam (WCK 5222) is under clinical development for treatment of Gram-negative infections.
Introduction b-Lactam antibiotics represent the most used class of antibacterial agents. These agents are generally well tolerated and effective, but their activity has been threatened by the rapid emergence and dissemination of b-lactamases.
1 Zidebactam (molecular formula C 13 H 21 N 5 O 7 S; Figure 1 ) is a non-b-lactam agent with a dual mechanism of action involving selective and high-affinity Gram-negative PBP2 binding and b-lactamase inhibition. 2 Owing to its PBP2 binding feature, standalone zidebactam demonstrates antibacterial activity against various Enterobacteriaceae and Pseudomonas. 3 Cefepime has a broad spectrum of activity against aerobic Gram-positive and -negative bacteria, including Pseudomonas aeruginosa, [4] [5] [6] and its clinical indications in the current US FDA product package insert include the treatment of moderate to severe pneumonia, complicated and uncomplicated urinary tract infections, complicated intra-abdominal infections and uncomplicated skin and skin-structure infections, as well as empirical therapy for febrile neutropenic patients. [7] [8] [9] Therefore, zidebactam combined with cefepime (WCK 5222) is under clinical development for treatment of Gram-negative infections (NCT02707107 and NCT02674347; www.clinicaltrials.gov).
Because zidebactam has potent in vitro antimicrobial activity against many Gram-negative species, the cefepime/zidebactam combination should be tested at a fixed ratio instead of a fixed concentration of zidebactam, which is generally used for b-lactamase inhibitor combinations when the b-lactamase inhibitor has limited antibacterial activity. We evaluated the in vitro activities of these two compounds separately and combined at 1:1 and 2:1 ratios when tested against a well-characterized collection of contemporary clinical isolates of b-lactamase-producing Gramnegative organisms.
Materials and methods

Organism collection
A total of 264 contemporary clinical isolates, including 193 strains producing the most clinically relevant b-lactamases, were evaluated. The isolates were collected worldwide through the SENTRY Antimicrobial Surveillance Program and screened for b-lactamase-encoding genes using the microarray-based assay Check-MDR CT101 kit (Check-Points, Wageningen, The Netherlands). The assay was performed according to the manufacturer's instructions. This kit has the capability to detect CTX-M groups 1, 2, 8!25 and 9, TEM WT and ESBL, SHV WT and ESBL, ACC, ACT/MIR, CMYII, DHA, FOX, KPC and NDM-1. The most common mutations that expand the spectrum of TEM and SHV enzymes are detected by this assay and these mutations include 104K, 164S/ C/H or 123S for TEM and 138S, 238A and 240K for SHV. Validation of the assay against US isolates was previously performed. 10 The isolates included in the collection are shown in Table 1 .
Susceptibility testing
MIC values were determined using CLSI broth microdilution methodology as described in CLSI document M07-A10. 11 The combination of cefepime/ zidebactam (WCK 5222; two ratio concentrations, 1:1 and 2:1) and both compounds alone were tested in 96-well, frozen-form panels produced by JMI Laboratories (North Liberty, IA, USA). Zidebactam and cefepime powders were provided by Wockhardt Bio AG (Switzerland) and the comparator agents were provided by the respective manufacturer or acquired from Sigma-Aldrich. Quality control (QC) isolates were tested in each test batch and the inoculum density was monitored by colony counts. QC ranges and interpretive criteria for the comparator compounds were as published in CLSI M100-S26. 12 Wockhardt Bio AG provided available target MIC information for cefepime/zidebactam and zidebactam alone tested against the listed QC organisms. The tested QC strains included the following: Escherichia coli ATCC 25922, ATCC 35218 and NCTC 13353, Klebsiella pneumoniae ATCC 700603 and ATCC BAA-1705 and P. aeruginosa ATCC 27853. Table 2 ).
Results
WT (cefepime susceptible) Enterobacteriaceae
b-Lactamase-producing Enterobacteriaceae
The MIC values of the cefepime/zidebactam combinations (2:1 and 1:1 ratios) were substantially lower than those of cefepime alone for ESBL-phenotype Enterobacteriaceae (Table 3) . Among CTX-M-producing isolates, significant reductions in cefepime MICs were noticeable with E. coli (MIC 50 .128, 0.5 and 0.25 mg/L for cefepime and cefepime/zidebactam at ratios of 2:1 and 1:1, respectively) and K. pneumoniae (MIC 50 64, 0.5 and 0.5 mg/L for cefepime and cefepime/zidebactam at ratios of 2:1 and 1:1, respectively). Overall, 85.7% of isolates were inhibited at 2 mg/L zidebactam alone. Furthermore, the MICs of 1:1 cefepime/zidebactam were generally 2-fold lower than those of 2:1 cefepime/zidebactam (Table 3) .
When tested against SHV-producing isolates, the (Table 3) . When tested against derepressed AmpC-producing isolates, the MICs of the cefepime/zidebactam combinations (MIC 50/90 0.12-0.25/0.5-1 mg/L) were 4-to 32-fold lower than those of cefepime alone (MIC 50/90 1/16 mg/L) and the MICs of cefepime/zidebactam 1:1 ratio were usually 2-fold lower than those of cefepime/zidebactam 2:1 ratio. Zidebactam alone was active against some plasmidic AmpC-producing isolates (MIC 50/90 0.25/16 mg/L) as well as some derepressed AmpC-producing isolates (MIC 50/90 2/>128 mg/L) ( 
P. aeruginosa and Acinetobacter baumannii
The MICs of the cefepime/zidebactam combinations (MIC 50/90 1/2 mg/L for both combinations) were generally 2-fold lower than those of cefepime and zidebactam alone (MIC 50/90 2/4 mg/L) when tested against cefepime-susceptible P. aeruginosa isolates ( 
Discussion
Infections caused by MDR Gram-negative bacteria represent a great challenge to infectious diseases clinicians. Most of these organisms harbour b-lactamase genes along with resistance determinants for other antimicrobial classes, resulting in multidrug resistance or pandrug resistance. 13 A variety of non-b-lactam agents are being studied in attempts to address MDR Gram-negative pathogens and Sader et al. Table 2 . WCK 5222 activity versus b-lactamase-producing strains JAC Table 3 . d Includes E. coli (7) and K. pneumoniae (3). It does not exclude the production of other b-lactamases.
e Includes C. freundii (5), C. koseri (1), E. aerogenes (4), E. cloacae (7) and S. marcescens (6). It does not exclude the production of other b-lactamases.
f Includes K. pneumoniae (24), C. freundii (2), E. coli (3), E. aerogenes (2), E. cloacae (1), P. mirabilis (1) and S. marcescens (2).
g Includes IMP producers [4; E. cloacae (1), K. oxytoca (1), K. pneumoniae (1) and S. marcescens (1)], NDM producers [8; E. coli (3), E. cloacae (1), K. pneumoniae (2), P. mirabilis (1) and S. marcescens (1)] and VIM producers [8; C. freundii (1), E. cloacae (4), K. pneumoniae (2) and P. mirabilis (1)].
Sader et al. Table 4 . WCK 5222 activity versus b-lactamase-producing strains JAC numerous investigational approaches have involved both established and new b-lactamase inhibitors in novel combinations. 14 The search for new inhibitor classes has been prompted in part by the rapid and continuous increase in the number of b-lactamases. In the last few years, new b-lactamase families have emerged with properties that make them more resistant to clavulanic acid and the sulfone inhibitors, thus encouraging the development of new approaches involving b-lactams.
1 Efforts to discover newer b-lactamase inhibitors over the last 25 years have resulted in very few compounds with an expanded inhibition spectrum and therefore no single b-lactamase inhibitor is able to offer a comprehensive coverage against all four classes of b-lactamases.
1,14 Moreover, novel b-lactamase inhibitors will continue to be challenged by emergence of newer mutant enzymes. 15, 16 Therefore, alternative approaches independent of b-lactamase inhibition need to be explored.
WCK 5222 consists of the combination of cefepime with zidebactam. Cefepime is a well-established fourth-generation cephalosporin with broad-spectrum activity, which includes P. aeruginosa and stably derepressed AmpC-producing Enterobacteriaceae; zidebactam is a non-b-lactam agent with intrinsic in vitro activity against some Gram-negative organisms due to its high affinity for PBP2 binding and b-lactamase inhibition properties. 2, [4] [5] [6] We evaluated the in vitro activity of each compound separately and the combination at two ratios (1:1 and 2:1) against a selected collection of Gram-negative organisms harbouring the most clinically relevant b-lactamases. The decision to combine the compounds in a fixed ratio instead of using a fixed concentration of the inhibitor (zidebactam) was driven by the fact that zidebactam exhibits potent in vitro antimicrobial activity against many Gram-negative species, such as E. coli, Enterobacter spp. and P. aeruginosa, including b-lactamase-producing strains. The highest zidebactam MICs for WT isolates of E. coli, Enterobacter spp. and P. aeruginosa were 0.12, 0.25 and 4 mg/L, respectively (Tables 2 and 4 ). In contrast, other Gram-negative organisms, such as S. marcescens, indole-positive Proteeae and Acinetobacter spp., appear to be intrinsically resistant to zidebactam. The in vitro activity of zidebactam against Klebsiella spp. was inconstant, with some isolates showing low MICs and others showing off-scale high MICs. Moreover, many Klebsiella spp. isolates exhibited trailing or haze growth in all or most zidebactam wells of the MIC panel.
When tested against Enterobacteriaceae, cefepime demonstrated potent in vitro activity against WT isolates as well as most AmpC-producing isolates. Although cefepime activity was compromised against Enterobacteriaceae producing ESBL and/or carbapenemases, cefepime/zidebactam combinations (2:1 and 1:1 ratios) demonstrated potent in vitro activities against Enterobacteriaceae producing most clinically relevant b-lactamases, including KPC, MBLs, CTX-M-15, SHV and AmpC. The highest cefepime/zidebactam (1:1) MIC among KPC-producing Enterobacteriaceae was only 2 mg/L and 90.0% of MBL-producing Enterobacteriaceae isolates were inhibited at cefepime/zidebactam 1:1 MIC of 8 mg/L (Table 3) . It is important to note that many b-lactamase-producing Enterobacteriaceae exhibited elevated MICs of cefepime and zidebactam when these were tested separately, but very low MICs of the cefepime/zidebactam combinations, emphasizing the synergy between these two compounds.
Cefepime/zidebactam combinations (2:1 and 1:1 ratios) were also very active against P. aeruginosa, including MBL-and AmpCproducing isolates (Table 4) . Furthermore, cefepime/zidebactam 1:1 was slightly (2-fold) more active than cefepime/zidebactam 2:1 against b-lactamase-producing Enterobacteriaceae and P. aeruginosa. When tested against OXA-producing (OXA-23/24/58) A. baumannii isolates, cefepime and zidebactam alone showed limited activity (MIC 50/90 128-.128/>128 mg/L). However, cefepime/ zidebactam 1:1 (MIC 50/90 , 32/32 mg/L) was at least 4-fold more active than cefepime or zidebactam tested alone.
The number of b-lactamases produced by clinically relevant bacterial species has increased astronomically in the last 10-20 years and this number continues to increase rapidly. 1, 10 Because it is not feasible to evaluate adequate numbers of all clinically relevant b-lactamases, this study focused on the most common b-lactamases observed in the last few years, mainly in Western Europe and the USA. Thus, some b-lactamases that are relatively common in some geographical regions, such as some MBLs (e.g. NDM, VIM and SPM), the class D enzymes OXA-48 (Enterobacteriaceae) and OXA-58 (A. baumannii) and some CTX-M variants (e.g. CTX-M-3 and CTX-M-14), were tested in small number or not included in this investigation. This is certainly a limitation of this study and the activity of WCK 5222 should be further evaluated against larger collections of organisms producing selected b-lactamases in future investigations.
In summary, WCK 5222 (cefepime/zidebactam) demonstrated potent in vitro activity against Enterobacteriaceae and P. aeruginosa, including isolates producing all four classes of clinically relevant b-lactamases. These in vitro results support further clinical development of cefepime/zidebactam for treatment of serious Gramnegative infections, especially those caused by MDR organisms.
